AusperBio concludes enrolment in Phase III AUSHINE trial
AHB-137 is an unconjugated antisense oligonucleotide developed using AusperBio's Med-Oligo platform.
Clinical Trials
South Korea and Australia offer solutions for radiopharma trial bottlenecks
Neurocrine’s Phase III trial of valbenazine for DCP fails to meet endpoints
UAE positions itself as a regional leader and a clinical trial hub
Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial
Altimmune reports positive topline results from IMPACT Phase IIb trial
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE
